Category Medicine and Healthcare
Press Release
April is Sjögren’s Awareness Month: Amplifying Patient Voices and Driving Awareness for an Underrecognized and Serious Autoimmune Disease
House resolution, national campaign, and patient voices shine a spotlight on one of the most prevalent-but misunderstood-autoimmune diseases. Read More
Press Release
CADIS HealthTech Launches EziExpert Remote Consultation and Enhanced Telehealth Platform With Augmented Reality, a Novel Platform That Transforms Any Connected Healthcare Assistant Into an Extension of the Remote Physician
Innovative dual teleconsultation platform enabling a remote physician to establish a simultaneous video call with the patient while also connecting in real-time with a healthcare assistant/nurse equipped with augmented reality (AR) smart glasses for more precise patient clinical assessments. Read More
Press Release
CBD Life Sciences Inc. (CBDL) Powers Forward with Disruptive Brain-Boosting Mushroom Applications
The global functional mushroom market is projected to reach $19.3 billion by 2030, driven by cutting-edge research revealing their potential to enhance memory, nerve growth, and overall cognitive health. Read More
Press Release
DEA’s Marijuana Legal Blunder and Loss: MMJ Serves Up an April Fools ‘Gift’ a Gut Punch LawSuit for Irreparable Harm
This April Fools' Day, the DEA Diversion isn't just the punchline-it's the entire joke. For the DEA, the joke's on them-and MMJ's legal team is doubling down. As Duane Boise MMJ's CEO quipped: “We'd send them a ‘Sorry For Your Loss' card, but we're too busy preparing for FDA clinical trials.” Read More
Press Release
ZetrOZ Systems to Showcase sam(R) Wearable Ultrasound Unit for Pro Football Trainers
During the PFATS meeting at the NFL Medical Summit, the inventors of sustained acoustic medicine will demonstrate the technology and present research showing its effectiveness in accelerating soft tissue healing. Read More
Press Release
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway -Company leveraging existing human pharmacokinetic data with TH104 -Advancing CMC plan to meet requirements of a New Drug Application Read More
Press Release
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025 FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast Read More
Press Release
Interactive Strength Inc. (Nasdaq: TRNR) Reports Fourth Quarter & Year-End 2024 Results
Company Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024 Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26 Quarterly Adjusted EBITDA Loss of $1.9 Million Reflects 42% Improvement YOY and 19% Sequentially Stockholders' Equity Was $7.1 Million at Year End Pending Acquisitions Remain on Track; TRNR Expects More than $50M in 2025 Pro Forma Revenue Read More
Press Release
DEA Forces Marijuana Pharma Drug Industry Offshore: A Symbol of DEA Systemic Obstruction Against Trump Administration Directives
"The DEA's marijuana approach is stuck in an outdated ‘war on drugs' mentality," said Duane Boise CEO of MMJ International Holdings. "While lawmakers push for medical progress, the DEA's red tape is suffocating innovation." DEA officials, including Matt Strait and Thomas Prevoznik, have been accused of imposing unnecessary hurdles, such as slow-walking API Bulk Manufacturing registrations, and imposing opaque approval processes while patients continue to suffer. Read More
Press Release
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets Read More
Press Release
Prolocor(R) Announces Publication in Circulation: Cardiovascular Interventions. Results Demonstrate That the Prolocor pFCG(TM) Test Predicts Risk of Subsequent Cardiovascular Events Regardless of Treatment Strategy (Percutaneous Coronary Intervention or Medical Management Alone)
Despite differences in characteristics and treatment, the pFCG test distinguished risk of the primary ischemic endpoint to a similar extent in the 2 groups. No significant association was observed between pFCG and risk of bleeding. Read More
Press Release
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need Read More
Press Release
Interactive Strength Inc. (Nasdaq:TRNR)'s FORME Named an Exclusive Wellness Partner for Virgin Atlantic's New Clubhouse at LAX
Partnership Raises FORME's Visibility with Affluent Customers, Highlights Brand's Seamless Integration into Premium Hospitality and Travel Environments Installation adds to Hospitality Customers such as Four Seasons, Bulgari and Mandalay Bay Resort Read More
Press Release
Candid Health Successfully Completed a Type 1 SOC 2 Examination With an Unqualified Opinion
Candid Health Reports on Security, Availability, and Confidentiality Standards Established by The American Institute of Certified Public Accountants (AICPA) for its Candid Health Revenue Cycle Automation Platform. Read More
Press Release
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer subgroup The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025, and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022 Read More
Press Release
CBD Life Sciences Inc. (CBDL) Launches Passion Fuel Cordyceps Complex - A Powerful Sexual Enhancement Supplement
The global sexual wellness market is projected to surpass $125 billion by 2026, with the supplement industry experiencing rapid growth as consumers seek natural solutions for enhanced performance and vitality. Read More
Press Release